13 clinical trials found.
-
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
The primary purpose of the study is to determine if a reduced dose of radiation to the whole brain and spine and less chemotherapy can ...Phase
TRIAL ROLE: Sub Investigator
-
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
The primary purpose of the study is to determine if accelerated BEP ((Bleomycin, Etoposide, and cisPlatin) is effective and tolerable for patients with advanced germ ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 3 Study of I-Metaiodobenzylguanidine (I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
?The primary purpose of the study is to determine the effectiveness and tolerability of the experimental drug I-MIBG or the experimental drug crizotinib for high ...Phase
TRIAL ROLE: Sub Investigator
-
Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma
The primary purpose is to determine the effectiveness and tolerability of eliminating therapy as the initial approach for infants <12 months of age and <18 ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 3 Study of I-Metaiodobenzylguanidine or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
?The primary purpose of the study is to assess the effectiveness and safety of targeted radiopharmaceutical therapy with 131I-MIBG or crizotinib for patients with high-risk ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1(NF1)
The purpose of the study is to find out the safety and efficacy of the drug selumetinib in treating patients with low-grade glioma. We want ...Phase
TRIAL ROLE: Sub Investigator
-
AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
The purpose of the study is to evaluate how stopping tyrosine kinase inhibitors (TKI) will affect treatment-free remission in patients with chronic myeloid leukemia (CML ...Phase
TRIAL ROLE: Sub Investigator
-
A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
The purpose of the study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia ...Phase
TRIAL ROLE: Sub Investigator
-
Site for ARST1431: A Randomized Phase 3 Study of Vincristine Dactinomycin Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) versus VAC/VI plus Temsirolimus (TORI Torisel NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
The purpose of the study is to determine the outcome for people with intermediate risk Rhabdomyosarcoma (RMS) by adding an experimental drug called temsirolimus to ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 3 Trial Investigating Blinatumomab (IND#117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma(B-LLy)
The purpose of the trial is to determine the safety and efficacy of the investigational medicine, blinatumomab plus standard treatment for patients who have Standard ...Phase
TRIAL ROLE: Sub Investigator
